Chen Jia, Zhang Xue, Zhang Guanyi, Zhu Fan, Liu Weiwei
Department of Laboratory Medicine, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China.
Department of Pathology, Affiliated Hospital of Chengdu University, Chengdu, 610081, China.
BMC Cancer. 2025 Feb 19;25(1):295. doi: 10.1186/s12885-025-13659-2.
To explore the potential of serum exosomal miRNAs as novel biomarkers for pancreatic ductal adenocarcinoma (PDAC).
Serum exosomal miRNAs were screened and verified by microarray analysis and quantitative real-time PCR (qRT-PCR) in patients with PDAC and healthy controls. The correlation between the clinical characteristics of PDAC and candidate exosomal miRNAs was analyzed, and the diagnostic performance of the candidate biomarkers was evaluated.
Serum exosomal miR-7977 and miR-451a were significantly upregulated in PDAC patients compared with healthy controls, and the levels of miR-7977 and miR-451a in serum exosomes were closely associated with the clinical stage and metastasis of PDAC patients. The area under curve (AUC) values of serum exosomal miR-7977 and miR-451a for PDAC were 0.825 and 0.804 in the training set and 0.796 and 0.830 in the validation set, respectively. A biomarker panel consisting of these two miRNAs resulted in a diagnostic power with an AUC of 0.901 in the training set and 0.918 in the validation set.
Serum exosomal miR-7977 and miR-451a might be diagnostic biomarkers for PDAC. These two miRNAs, when combined, exhibit optimal diagnostic performance.
探讨血清外泌体微小RNA（miRNA）作为胰腺导管腺癌（PDAC）新型生物标志物的潜力。
通过微阵列分析和定量实时聚合酶链反应（qRT-PCR）对PDAC患者和健康对照者的血清外泌体miRNA进行筛选和验证。分析PDAC临床特征与候选外泌体miRNA之间的相关性，并评估候选生物标志物的诊断性能。
与健康对照相比，PDAC患者血清外泌体miR-7977和miR-451a显著上调，血清外泌体中miR-7977和miR-451a的水平与PDAC患者的临床分期和转移密切相关。血清外泌体miR-7977和miR-451a对PDAC的曲线下面积（AUC）值在训练集中分别为0.825和0.804，在验证集中分别为0.796和0.830。由这两种miRNA组成的生物标志物组合在训练集中的诊断效能AUC为0.901，在验证集中为0.918。
血清外泌体miR-7977和miR-451a可能是PDAC的诊断生物标志物。这两种miRNA联合使用时表现出最佳的诊断性能。
